ADRIANA VIDAL FERNANDES MASSICANO

ADRIANA VIDAL FERNANDES MASSICANO

Página do item completo

Resultados de Busca

Agora exibindo 1 - 5 de 5

Development and biological studies of sup(177)Lu-DOTA-rituximab for the treatment of non-hodgkin's lymphoma
2016 - MASSICANO, ADRIANA V.F.; PUJATTI, PRISCILLA B.; ALCARDE, LAIS F.; SUZUKI, MIRIAM F.; SPENCER, PATRICK J.; ARAUJO, ELAINE B.
The optimization of DOTA-NHS-ester conjugation to Rituximab using different Ab:DOTA molar ratios (1:10, 1:20, 1:50 and 1:100) was studied. High radiochemical yield, in vitro stability and immunoreactive fraction were obtained for the Rituximab conjugated at 1:50 molar ratio, resulting in the incorporation of an average number of 4.9 ± 1.1 DOTA per Rituximab molecule. Labeling with 177Lu was performed in high specific activity with great in vitro stability. Biodistribution in healthy and xenographed mice showed tumor uptake and high in vivo stability as evidenced by low uptake in bone. The properties of 177Lu-DOTA-Rituximab prepared from DOTA-NHS-ester suggest the potential for the application of the 177Lu-labeled antibody in preliminary clinical studies.
Radiolabeling parameters of sup(177)Lu-dota-rituximab
2013 - MASSICANO, ADRIANA V.F.; ALCARDE, LAIS F.; OLIVEIRA, RICARDO S.; MENGATTI, JAIR; ARAUJO, ELAINE B. de
Standardization of methodology to derivatization and radiolabeling of the anti-CD20 monoclonal antibody from bifunctional chelator dota-nhs-ester
2009 - MASSICANO, ADRIANA V.F.; AKANJI, AKINKUNMI G.; SANTOS, JOSEFINA S.; PUJATTI, PRISCILLA B.; COUTO, RENATA M.; MASSICANO, FELIPE; ARAUJO, ELAINE B.
Mass influence of DOTA-Rituximab in the radiolabelling with Lu-177
2011 - ARAUJO, ELAINE B. de; MASSICANO, ADRIANA V.F.; PUJATTI, PRISCILLA B.
Development of a new bombesin analog radiolabelled with lutetium-177
2010 - PUJATTI, P.B.; SANTOS, J.S.; MASSICANO, A.V.F.; MENGATTI, J.; ARAUJO, E.B. de
In this work we describe the first results of radiolabeling with lutetium-177 (177Lu) and in vivo biodistribution and pharmacokinetics studies in normal Balb-c mice of a new bombesin analog (BEFG2) – DOTA-Phe-X-BBN(6-14), where X is a spacer of two aminoacids. Bombesin (BBN) is an amphibian analog of human gastrin releasing peptide (GRP). Development of radiolabeled BBN derivatives as agents for diagnostic imaging and systemic radiotherapy has increased considerable because of the observation that GRP receptors (GRPr) are over-expressed in a variety of human tumor cells, such as prostate tumor cells. 177Lu-labeled peptides are attractive due to the excellent radiophysical properties and commercial availability of the radiometal. BEFG2 was successfully labeled with high yield and kept stable for more than 96 hours at 2-8º C and 1 hour in human plasma. Data analysis obtained from the in vivo studies showed that the amount of BEFG2 present in plasma decreased rapidly and became almost undetectable at 60 min p.i., indicating rapid peptide excretion, which is performed mainly by renal pathway. In addition, biodistribution and single photon emission tomography showed low abdominal accumulation of 177Lu-DOTA- Phe-X-BBN(6-14), indicating that this analog is a potential candidate for tumors target therapy.